The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $400.12

Today's change0.00 0.00%
Updated December 24 1:00 PM EST. Delayed by at least 15 minutes.
 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $400.12

Today's change0.00 0.00%
Updated December 24 1:00 PM EST. Delayed by at least 15 minutes.

Regeneron Pharmaceuticals Inc closed at (U.S.)$400.12.

Shares have lost 2.64% over the last five days, but have gained 45.37% over the last year to date. This security has outperformed the S&P 500 by 31.58% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $400.12
  • High--
  • Low--
  • Bid / Ask-- / --
  • YTD % change+45.37%
  • Volume0
  • Average volume (10-day)946,406
  • Average volume (1-month)757,497
  • Average volume (3-month)829,096
  • 52-week range(U.S.) $262.97 to (U.S.) $437.64
  • Beta0.83
  • Trailing P/E135.83×
  • P/E 1 year forward40.15×
  • Forward PEG1.99×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $2.95
Updated December 24 1:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+12.74%

Based on its net profit margin of 12.74%, Regeneron Pharmaceuticals Inc is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.10%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue726666626610
Total other revenue--------
Total revenue726666626610
Gross profit643556545562
Total cost of revenue821108148
Total operating expense543454440398
Selling / general / administrative123397182
Research & development338295287268
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)011----
Other operating expenses, total--------
Operating income183212186212
Interest income (expense), net non-operating-9-10-12-12
Gain (loss) on sale of assets--------
Other--------
Income before tax176203175198
Income after tax80936597
Income tax, total96110110101
Net income80936597
Total adjustments to net income--------
Net income before extra. items80936597
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items80936597
Inc. avail. to common incl. extra. items80936597
Diluted net income83936583
Dilution adjustment300-14
Diluted weighted average shares11711311299
Diluted EPS excluding extraordinary itemsvalue per share0.700.820.580.84
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share0.700.860.580.84